Proteintech, HebeCell to develop cancer immunotherapies

By The Science Advisory Board staff writers

Proteintech and HebeCell have announced a partnership to develop nanobody-based chimeric antigen receptors (nCARs) for cancer cellular immunotherapy use.

The nCAR technology will be used to develop induced pluripotent stem cells (iPSCs) -derived natural killer cells, according to the firms. Proteintech recently acquired ChromoTek, which augmented its nanobody development resources, while HebeCell holds intellectual property regarding natural killer cells.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?